354 related articles for article (PubMed ID: 2385731)
21. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
[TBL] [Abstract][Full Text] [Related]
22. The use of surgery for the treatment of prolactinomas.
van't Verlaat JW
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
[TBL] [Abstract][Full Text] [Related]
23. [Bromocriptine for macroprolactinomas. Discussion of 3 cases treated successfully].
Sapunar J; López JM; Huete I; Tagle R
Rev Med Chil; 1992 Feb; 120(2):168-73. PubMed ID: 1340555
[TBL] [Abstract][Full Text] [Related]
24. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
25. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
26. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
[TBL] [Abstract][Full Text] [Related]
27. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
28. [Treatment strategy of pituitary invasive prolactinomas].
Wu ZB; Yu CJ
Zhonghua Wai Ke Za Zhi; 2009 Jan; 47(2):123-7. PubMed ID: 19563008
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
30. Treatments of multi-invasive giant prolactinoma.
Yang MY; Shen CC; Ho WL
J Clin Neurosci; 2004 Jan; 11(1):70-5. PubMed ID: 14642373
[TBL] [Abstract][Full Text] [Related]
31. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
32. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
33. Hyperprolactinaemia in males: a heterogeneous disorder.
Walsh JP; Pullan PT
Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
[TBL] [Abstract][Full Text] [Related]
34. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
35. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
[TBL] [Abstract][Full Text] [Related]
36. [Immediate efficacy of bromocriptine (BrC)-LAR in the treatment of macroprolactinomas: apropos of a case].
García Calzado MC; Ruiz Buendía A
Rev Clin Esp; 1992 Jun; 191(2):112-3. PubMed ID: 1502384
[No Abstract] [Full Text] [Related]
37. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
[TBL] [Abstract][Full Text] [Related]
38. [Prolactinoma in man: clinical and histological characteristics].
Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
[TBL] [Abstract][Full Text] [Related]
39. Demographic characteristics, presentations and treatment outcome of patients with prolactinoma.
Malik S; Hussain SZ; Basit R; Idress N; Habib A; Zamant M; Islam N
J Ayub Med Coll Abbottabad; 2014; 26(3):269-74. PubMed ID: 25671924
[TBL] [Abstract][Full Text] [Related]
40. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
